ICH Q5A(R2) is the key regulatory guidance document for the viral safety evaluation of cell lines used in the manufacture of biologics. This guideline now specifically references Next Generation Sequencing (NGS) as an advanced virus testing tool and an ethical replacement for virus assays in animal models. In collaboration with Charles River Laboratories, Pathoquest has generated data which underscores the superiority of their GMP validated iDTECT® Transcriptome assay over MAP/HAP/RAP in the characterization of rodent cell lines. This assay harnesses the power of NGS to screen cell lines for any replicating viral contaminants and allows the replacement of two mandatory animal-based assays: in vivo adventitious virus and MAP/HAP/RAP testing.
In the second part of a two-part interview, Paz Vellanki of Precision for Medicine explains which confirmatory evidence can support a single-trial approval and why she expects FDA's rare disease framework to last.
FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.
FDA declined to approve Summit Therapeutics and Akeso’s ivonescimab plus chemotherapy in previously treated EGFR-mutated NSCLC. The agency said the Phase 3 HARMONi trial’s progression-free survival benefit was not enough without a significant overall survival gain.
J&J agreed to acquire Ollin Biosciences for $2.2 billion upfront, and Lilly agreed to buy Calytrix Bio for up to $1.5 billion. Novartis licensed OBI Pharma’s ADC platform, and Seawolf debuted with $100 million and a Sanofi pact.
Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.